Bacteriophage-Enriched Galenic for Intrapericardial Ventricular Assist Device Infection
Overview
Authors
Affiliations
We report a case of severe outflow graft infection following left ventricular assist device (LVAD) implantation. A 51-year old male LVAD patient was readmitted to our hospital presenting signs of systemic infection. One year previously, LVAD implantation (HeartMate3, Abbott, Chicago, IL, USA) with concomitant patent foramen ovale closure had been performed in the context of end-stage heart failure due to dilative cardiomyopathy (INTERMACS III). The indication for LVAD-therapy was bridge-to-candidacy, since the patient did not instantly fulfill all criteria for cardiac transplantation. At admission, a PET-CT scan unveiled fluid accumulation, encircling the outflow-graft prosthesis (SUV 10.5) with contrast-enhancement involving the intrathoracic driveline (SUV 11.2). Since cardiac transplantation was not feasible, the patient underwent surgical revision. In the first step, redo sternotomy was performed with local debridement, including jet lavage. Intraoperative swabs confirmed bacterial infection with . Following this, the patient underwent negative pressure wound therapy (NPWT) with instillation using the V.A.C. VERAFLO system (KCI-3M, San Antonio, TX, USA) for a total of 19 days. Due to the severity of infection, local bacteriophage application was performed within the wound closure. In order to concentrate phage therapy at the infection site, phages were applied using a novel semi-fluid galenic. After wound closure, the patient was discharged with an uneventful course. A control PET-CT scan 3 months after discharge showed a significant decrease in infection (outflow graft: SUV 7.2, intrathoracic driveline: SUV 3.0) correlated with contrast enhancement. Bacterial infection of intrathoracic VAD components represents a severe and potentially life-threatening complication. If cardiac transplantation is not feasible, complex wound management strategies are required. Local bacteriophage therapy might be a promising addition to already established therapeutical options. In order to improve bacteriophage retention at the wound site, application of a viscous galenic might be beneficial.
Passerini M, Petri F, Suh G Pathogens. 2024; 13(5).
PMID: 38787276 PMC: 11123972. DOI: 10.3390/pathogens13050424.
ventricular assist device infections: findings from ineffective phage therapies in five cases.
Aslam S, Roach D, Nikolich M, Biswas B, Schooley R, Lilly-Bishop K Antimicrob Agents Chemother. 2024; 68(4):e0172823.
PMID: 38470133 PMC: 10989018. DOI: 10.1128/aac.01728-23.
Schramm R, Kirchner J, Ibrahim M, Rojas S, Morshuis M, Rudolph V J Clin Med. 2024; 13(2).
PMID: 38256596 PMC: 10816947. DOI: 10.3390/jcm13020462.
Simpson E, MacLeod C, Stacey H, Nagy J, Jones J Antibiotics (Basel). 2023; 12(12).
PMID: 38136718 PMC: 10740750. DOI: 10.3390/antibiotics12121684.
Racenis K, Lacis J, Rezevska D, Mukane L, Vilde A, Putnins I Viruses. 2023; 15(5).
PMID: 37243293 PMC: 10223274. DOI: 10.3390/v15051210.